|
||||||||
|---|---|---|---|---|---|---|---|---|
| Agent name and WHO code | UN 1969 | WHO 1970 | BWC 1992 | Australia Group* 2006 | NATO 1996 | CDC Category** 2007 | NIAID NIH Category*** 2007 | BWC draft 2001 | BACTERIAL AGENTS |
| Anthrax A22 | X | X | X | X | X | A | A | X |
| Trench Fever A79.0 | X | |||||||
| Botulinum Toxins A05.1 | X | A | A | |||||
| Brucellosis A23 | X | X | X | X | X | B | B | X |
| Clostridium perfringens A05.2 | X | B | B | |||||
| Glanders A24.0 | X | X | X | X | B | B | X | |
| Melioidosis A24 | X | X | X | X | X | B | B | X |
| Tularaemia A21 | X | X | X | X | X | A | A | X |
| E. coli A04.4 | X | B | B | |||||
| Typhoid Fever A01.0 | X | X | X | X | ||||
| Salmonella A02.0 | X | B | B | |||||
| Shigellosis A03 | X | X | B | |||||
| Staphylococcal Enterotoxin B A41.0 | X | B | B | |||||
| Cholera A00 | X | X | X | B | B | |||
| Plague A20 | X | X | X | X | X | A | A | X | VIRAL AGENTS |
| Korean Haemorrhagic Fever A98.5 | X | X | X | C | A | |||
| Sin nombre J12.8 | X | C | A | X | ||||
| Crimean-Congo Haemorrhagic Fever A98.0 | X | X | X | C | X | |||
| Rift Valley Fever A92.4 | X | X | X | A | X | |||
| Ebola A98.3 | X | X | A | A | X | |||
| Marburg A98.4 | X | X | A | A | X | |||
| Lymphocytic chriomeningitis A87.2 | X | A | ||||||
| Argentine Hemorrhagic Fever A96.0 | X | X | A | A | X | |||
| Bolivian Hemorrhagic Fever A96.1 | X | X | A | X | ||||
| Lassa Fever A96.2 | X | X | A | A | X | |||
| Tick-borne encephalitis A84.0/A84 | X | X | X | X | C | X | ||
| Dengue A90/91 | X | X | X | X | A | |||
| Yellow fever A95 | X | X | X | X | C | X | ||
| Omsk Hemorrhagic Fever A98.1 | X | X | A | |||||
| Japanese Encephalitis A83.0 | X | X | B | |||||
| Western Equine encephalomyelitis A83.1 | X | X | B | B | X | |||
| Eastern Equine encephalomyelitis A83.2 | X | X | X | B | B | X | ||
| Chikungunya A92.0 | X | X | X | X | C | |||
| O'nyong-nyong A92.1 | X | |||||||
| Venezuelan equine encephalomyelitis A92.2 | X | X | X | X | X | B | B | X |
| Smallpox B03 | X | X | X | X | A | A | X | |
| Monkey pox B04 | X | A | X | |||||
| White pox (a variant of variola virus) | X | A | ||||||
| Influenza J10,11 | X | X | X | C | TOXINS |
|||
| Ricin | X | B | B | FUNGI |
||||
| Coccidioidomycosis B38 | X | X | X | |||||
| Trichothecene Mycotoxins | RICKETTSIA |
|||||||
| Q Fever A78 | X | X | X | X | X | B | B | X |
| Scrub Typhus A75.3 | X | C | ||||||
| Typhus Fever A75 | X | X | X | X | X | B | B | X |
| Rocky Mountain Spotted Fever A77 | X | X | X | C | CHLAMYDIA |
|||
| Psittacosis A70 | X | X | X | B | B |
*Australia Group
The Australia Group is an informal group committed to cooperative efforts to end the use of chemical and biological weapons through restrictions on production and trade of CBW materials. The Austrialia Group (AG) first met in June 1985 with 15 members but now includes 40 members and the European Community as an observer.
Argentina; Australia; Austria; Belgium; Bulgaria; Canada; Croatia; Cyprus; Czech Republic; Denmark; Estonia; Finland; France; Germany; Greece; Hungary; Iceland; Ireland; Italy; Japan; Latvia; Lithuania; Luxembourg; Malta; Netherlands; New Zealand; Norway; Poland; Portugal; Romania; Slovak Republic; South Korea; Slovenia; Spain; Sweden; Switzerland; Turkey; Ukraine; United Kingdom; United States; European Community Commission (Observer)
**Category A Diseases/Agents
The U.S. public health system and primary healthcare providers must be prepared to address various biological agents, including pathogens that are rarely seen in the United States. High-priority agents include organisms that pose a risk to national security because they
- can be easily disseminated or transmitted from person to person;
- result in high mortality rates and have the potential for major public health impact;
- might cause public panic and social disruption; and
- require special action for public health preparedness.
Category B Diseases/Agents
Second highest priority agents include those that
- are moderately easy to disseminate;
- result in moderate morbidity rates and low mortality rates; and
- require specific enhancements of CDC's diagnostic capacity and enhanced disease surveillance.
Category C Diseases/Agents
Third highest priority agents include emerging pathogens that could be engineered for mass dissemination in the future because of
- availability;
- ease of production and dissemination; and
- potential for high morbidity and mortality rates and major health impact.
***NIAID NIH Category A, B & C Priority Pathogen
Similar to the CDC categories of biological agents, these category labels are issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institute of Health (NIH).
|
NEWSLETTER
|
| Join the GlobalSecurity.org mailing list |
|
|
|
